Street gushes over Alzheimer’s drug, but some worry about overreaction

Analysts split in their reactions to Biogen Idec’s report of test results for its new Alzheimer’s drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.